Literature DB >> 2641640

Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys.

G P Dutta1, S K Puri, A P Bhaduri, M Seth.   

Abstract

An analogue of primaquine, N1-(3-acetyl-4-5-dihydro-2-furanyl)-N4-(6-methoxy-8-quinolinyl) 1,4-pentanediamine, CDRI Code 80/53), has been evaluated for anti-relapse activity against sporozoite induced Plasmodium cynomolgi B infection in rhesus monkeys. The compound has shown 100% curative anti-relapse activity at 1.25 mg/kg x 7 day dose schedule, thereby giving a primaquine index of 0.8. The compound is currently under Phase-I clinical trials.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2641640     DOI： 10.4269/ajtmh.1989.41.635

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  9 in total

Review 1.  A pre-emptive strike against malaria's stealthy hepatic forms.

Authors:  Dominique Mazier; Laurent Rénia; Georges Snounou
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

Review 2.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

3.  Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand.

Authors:  Srivicha Krudsood; Polrat Wilairatana; Noppadon Tangpukdee; Kobsiri Chalermrut; Siripun Srivilairit; Vipa Thanachartwet; Sant Muangnoicharoen; Natthanej Luplertlop; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Korean J Parasitol       Date:  2006-09       Impact factor: 1.341

4.  Plasmodium vivax polymorphism in a clinical drug trial.

Authors:  T Adak; N Valecha; V P Sharma
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 5.  New insight-guided approaches to detect, cure, prevent and eliminate malaria.

Authors:  Sushil Kumar; Renu Kumari; Richa Pandey
Journal:  Protoplasma       Date:  2014-10-17       Impact factor: 3.356

6.  8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; M Nasr; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

7.  A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide-responsive uncomplicated falciparum malaria [ISCRTN50134587].

Authors:  N J Gogtay; K D Kamtekar; S S Dalvi; S S Mehta; A R Chogle; U Aigal; N A Kshirsagar
Journal:  BMC Infect Dis       Date:  2006-02-01       Impact factor: 3.090

Review 8.  Modeling Relapsing Malaria: Emerging Technologies to Study Parasite-Host Interactions in the Liver.

Authors:  Annemarie Voorberg-van der Wel; Clemens H M Kocken; Anne-Marie Zeeman
Journal:  Front Cell Infect Microbiol       Date:  2021-01-29       Impact factor: 5.293

9.  KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro.

Authors:  Anne-Marie Zeeman; Sandra M van Amsterdam; Case W McNamara; Annemarie Voorberg-van der Wel; Els J Klooster; Alexander van den Berg; Edmond J Remarque; David M Plouffe; Geert-Jan van Gemert; Adrian Luty; Robert Sauerwein; Kerstin Gagaring; Rachel Borboa; Zhong Chen; Kelli Kuhen; Richard J Glynne; Arnab K Chatterjee; Advait Nagle; Jason Roland; Elizabeth A Winzeler; Didier Leroy; Brice Campo; Thierry T Diagana; Bryan K S Yeung; Alan W Thomas; Clemens H M Kocken
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.